Calcium binding proteins
OwnerPeter Sonderegger, Gustav Hintsch +5inventors
InventorsPeter Sonderegger, Gustav Hintsch, Jochen Kinter, Virginija Meskenaite, Sabine Schrimpf, Lorenz Vogt, Andreas Zurlinden
Life of this patent
Estimating the term…
Abstract
There is described a novel class of calcium binding proteins of the nervous system, in particular calsyntenin-1-3. Calsyntenin proteins are valuable agents in the treatment of disorders of the nervous system, in particular the central nervous system. They are very useful for the development of drugs for the treatment of disorders of the nervous system.
Claims42
An isolated polypeptide for the use as a pharmaceutical comprising an amino acid sequence at least 50% identical to a sequence selected from the group consisting of:
- a) a full length amino acid sequence selected from the group consisting of Seq. Id. No. 2, Seq. Id. No. 4 and Seq. Id. No. 6,
- b) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of:
- sequence of residues from about 46 to about 165, sequence of residues 166 to about 257, sequence of residues from about 774 to about 861 and sequence of residues from about 881 to about 981 of Seq. Id. No. 2,
- c) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of:
- sequence of residues from about 66 to about 158, sequence of residues from about 182 to about 259, sequence of residues from about 751 to about 834 and sequence of residues from about 854 to about 955 of Seq. Id. No. 4,
- d) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of:
- sequence of residues from about 51 to about 142, sequence of residues from about 167 to about 244, sequence of residues from about 759 to about 845 and sequence of residues from about 869 to about 956 of Seq Id. No. 6
- e) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of:
- sequence of residues from about 881 to about 981 of Seq. Id. No. 2, sequence of residues from about 854 to about 955 of Seq. Id. No. 4 and sequence of residues from about 869 to about 956 of Seq Id. No. 6,
- and having calcium binding activity and/or the capacity to bind to the Arp2/3 complex.
An isolated polypeptide for the use as a pharmaceutical comprising an amino acid sequence selected from
- sequences comprising a stretch of at least 100 amino acids with a minimal identity percentage of 50%, preferably 55% and more preferably 60% to a amino acid sequence selected from the group consisting of Seq. Id. No. 2, Seq. Id. No. 4 and Seq. Id. No. 6, said sequences having calcium binding activity and/or the capacity to bind to the Arp2/3 complex.
The polypeptide according to anyone of the preceding claims which
- is a transmembrane protein and which
- is expressed predominatly in cells of the nervous system.
The polypeptide according to anyone of the preceding claims which has its major calcium-binding domain in the cytoplasmic compartment.
The polypeptide according to anyone of the preceding claims which has at least one binding site for the Arp2/3 complex.
An isolated nucleotide sequence encoding a polypeptide according to anyone of the preceding claims for the use as pharmaceutical.
An isolated nucleotide sequence encoding a polypeptide as defined in anyone of the preceding claims which has, due to at least one point mutation, insertion or deletion, lost its function.
Use of a polypeptide or a partial sequence thereof as defined in anyone of the preceding claims for the use as a tool for the development of a pharmaceutical.
Use of a protein or a DNA sequence as defined in anyone of the preceding claims for the screening and for the preparation of a medicament for the treatment of disorders, in particular disorders of the nervous system, more particular of the central nervous system, most preferably the brain.
An isolated polypeptide comprising an amino acid sequence which is at least 60% identical to the amino acid sequence of Seq.Id. No. 4.
An isolated polypeptide comprising an amino acid sequence which is at least 98.5% identical to the amino acid sequence of Seq. Id. No. 6.
39 The polypeptide of claim 37 which is identical to Seq. Id. No. 6.
Dependencies are inferred from the claim text.